Trials / Completed
CompletedNCT00525668
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Charite University, Berlin, Germany · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Hypothesis: Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination (EDSS and MSFC).
Detailed description
This multicentric, national study investigates the efficacy and safety of EGCG in patients with relapsing-remitting multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | epigallocatechin-gallate (Sunphenon) | 200 mg twice daily, after 3 months 400 mg twice daily |
| DRUG | placebo | 2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2007-09-06
- Last updated
- 2021-07-29
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00525668. Inclusion in this directory is not an endorsement.